Abstract
CLINICAL QUESTION Is long-term (>= 3 months) vs short-term therapy with vitamin K antagonists (VKAs) associated with differences in the incidence of recurrent venous thromboembolism (VTE), major bleeding, and mortality in patients with symptomatic VTE? BOTTOM LINE Long-term treatment with VKAs is associated with a reduced risk for recurrent VTE and an increased risk for major bleeding compared with short-term treatment in patients with VTE, but is not associated with differences in mortality
Original language | English |
---|---|
Pages (from-to) | 72-73 |
Journal | JAMA |
Volume | 314 |
Issue number | 1 |
DOIs | |
Publication status | Published - 2015 |